JERUSALEM--(BUSINESS WIRE)--BioLineRx (TASE:BLRX) today announced that it has been advised by Royalty Pharma, the new parent company of Cypress Bioscience Inc., that it is committed to enhance the value of Cypress’ pipeline assets, which include BioLineRx’s BL-1020 (CYP-1020) compound, a novel therapeutic for schizophrenia. The clinical program for BL-1020 will be spearheaded by the Cypress development team, and together they intend to pursue the program’s continuation.
